Overview

BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This was a 52-week, non-comparative, uncontrolled study of paroxetine in Japanese PTSD patients to obtain clinical experience regarding efficacy and safety. In this study, subjects received paroxetine 20mg-40mg once daily after an evening meal.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Paroxetine